Concerns Raised Over EU Wastewater Regulation Impacting Drug Supply

The European Parliament has urged the European Commission to reassess its proposed Municipal Wastewater Directive (KARL), highlighting potential threats to the secure supply of essential medications. In a recent report addressing the water resilience strategy, lawmakers expressed that the current iteration fails to adequately consider the implications for pharmaceutical availability.

Manufacturers have voiced strong opposition to the new regulation, which requires the introduction of a fourth treatment stage aimed at removing micro-pollutants. This regulation also imposes a cost-sharing requirement, mandating specific sectors, including pharmaceutical and cosmetic manufacturers, to cover at least 80% of the expenses associated with establishing this enhanced treatment level.

Industry representatives have warned that these obligations could lead to significant drug shortages and undermine Germany's competitive position in the pharmaceutical sector. The organization Pharma Deutschland has welcomed the Parliament's call for revisions, urging the swift adoption of the initiative to ensure that both environmental and supply concerns are appropriately addressed.

Bork Bretthauer, the managing director of Pro Generika, echoed these sentiments, cautioning that the proposed Municipal Wastewater Directive could create a 'tsunami of shortages.' He emphasized that the goal of achieving cleaner water must not compromise the security of medication supplies, which is contrary to the Commission's aim of establishing a more stable drug supply chain.

Critics of the directive point out that the proposed cost distribution does not take into account that pharmaceutical residues primarily enter wastewater through the excretion of patients. The anticipated annual costs, estimated at around one billion euros, would disproportionately burden generic drug manufacturers.

Bretthauer stressed the urgent need for a revised impact assessment that balances the dual objectives of ensuring clean water while maintaining a secure supply of medications. As discussions continue, it remains crucial for policymakers to find an equilibrium that safeguards public health and environmental standards without jeopardizing access to essential pharmaceuticals.